Pharmaceutical - Anti-virals, USA

Filter

Current filters:

Anti-viralsUSA

Popular Filters

1 to 25 of 33 results

Sanofi Pasteur gains FDA approval of Fluzone Intradermal Quadrivalent for adults

Sanofi Pasteur gains FDA approval of Fluzone Intradermal Quadrivalent for adults

13-12-2014

French pharma major Sanofi’s vaccines division, Sanofi Pasteur, has received approval from the US Food…

Anti-viralsFluzonePharmaceuticalRegulationSanofiSanofi PasteurUSAVaccines

AbbVie signs agreement with Medicines Patent Pool for lopinavir and retonavir in pediatric HIV

AbbVie signs agreement with Medicines Patent Pool for lopinavir and retonavir in pediatric HIV

01-12-2014

US drugmaker AbbVie and the Medicines Patent Pool have agreed a licensing agreement for lopinavir and…

AbbVieAnti-viralsLopinavirPharmaceuticalResearchRitonavir TabletsUSA

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

27-11-2014

US pharma major Bristol-Myers Squibb has received a Complete Response Letter from the US Food and Drug…

Anti-viralsBristol-Myers SquibbdaclatasvirPharmaceuticalRegulationUSA

New data show strong cure rates with AbbVie’s hep C therapy in HIV and transplant patient studies

New data show strong cure rates with AbbVie’s hep C therapy in HIV and transplant patient studies

11-11-2014

US pharma company AbbVie got a boost for its upcoming hepatitis C treatment regimen, with the company…

AbbVieAnti-viralsPharmaceuticalResearchUSA

Merck’s triple-therapy hepatitis C regimen shows sub-optimal efficacy

Merck’s triple-therapy hepatitis C regimen shows sub-optimal efficacy

11-11-2014

US pharma giant Merck & Co has admitted that interim data from its triple-therapy regimen in hepatitis…

Anti-viralsHCVHepatitis CHepatitis C virusMerck & CoPharmaceuticalResearchsofosbuvirUSA

EFPIA and IMI launch 280 million-euro Ebola program, calling for proposals

EFPIA and IMI launch 280 million-euro Ebola program, calling for proposals

10-11-2014

The European Federation of Pharmaceutical Industries and Associations, its specialized group Vaccines…

Anti-viralsEuropeFinancialPharmaceuticalResearchUSA

US lawmakers introduce Bill to speed Ebola treatments development

30-10-2014

Two US Senators have announced their intention to introduce a bill to speed the development of treatments…

Anti-viralsLegalPharmaceuticalResearchTropical diseasesUSAVaccines

EMA urging firms with Ebola candidates to seek orphan status

21-10-2014

The European Medicines Agency is aiming to encourage developers of treatments or vaccines against Ebola…

Anti-viralsEuropePharmaceuticalRare diseasesRegulationResearchUSA

Bristol-Myers resolves Sustiva patent litigation in USA

Bristol-Myers resolves Sustiva patent litigation in USA

08-10-2014

US pharma major Bristol-Myers Squibb has successfully resolved all outstanding US patent litigation relating…

Anti-viralsAtriplaBristol-Myers SquibbCiplaLegalMerck & CoPatentsPharmaceuticalSustivaUSA

Johnson & Johnson to acquire Alios BioPharma

Johnson & Johnson to acquire Alios BioPharma

30-09-2014

US health care giant Johnson & Johnson has signed a definitive agreement to acquire Alios BioPharma,…

AL-8176Alios BioPharmaAnti-viralsJohnson & JohnsonMergers & AcquisitionsPharmaceuticalUSA

US Pharma now developing 44 drugs/vaccines for HIV/AIDS

11-09-2014

The USA’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for…

Anti-viralsPharmaceuticalResearchUSAVaccines

ViiV Healthcare gains FDA approval for HIV drug Triumeq

ViiV Healthcare gains FDA approval for HIV drug Triumeq

23-08-2014

The US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine…

Anti-viralsGlaxoSmithKlinePfizerPharmaceuticalRegulationShionogiTriumeqUSAViiV Healthcare

Achillion soars on positive mid-stage hep C drug combo trial

Achillion soars on positive mid-stage hep C drug combo trial

17-08-2014

US drugmaker Achillion saw its share rocket 18.4% to a 52-week high of $9.99 in pre-market trading on…

ACH-3102AchillionAnti-viralsHepatitis C virusPharmaceuticalResearchsofosbuvirSovaldiUSA

Sanofi Pasteur announces positive results for Fluzone’s higher dose

Sanofi Pasteur announces positive results for Fluzone’s higher dose

14-08-2014

Sanofi Pasteur, the vaccines division of French drug major Sanofi, has found that Fluzone High-Dose was…

Anti-viralsFluzonePharmaceuticalResearchSanofiSanofi PasteurUSAVaccinationVaccines

US court orders SIGA to pay PharmAthene lump sum expectation damages

US court orders SIGA to pay PharmAthene lump sum expectation damages

11-08-2014

USA-based biodefense company PharmAthene says that, on Friday, the Delaware Court of Chancery issued…

Anti-viralsDelaware Court of ChanceryFinancialLegalPharmaceuticalPharmAtheneSIGA TechnologiesTecovirimatUSA

FDA modifies Tekmira's TKM-Ebola clinical hold to partial hold

FDA modifies Tekmira's TKM-Ebola clinical hold to partial hold

08-08-2014

Canadian RNA interference (RNAi) therapeutics developer Tekmira Pharmaceuticals revealed yesterday that…

Anti-viralsEbolaMicrobiologyPharmaceuticalRegulationResearchTekmira PharmaceuticalsTKM-EbolaUS Food and Drug AdministrationUSA

Biota tanks as flu drug candidate disappoints

Biota tanks as flu drug candidate disappoints

04-08-2014

USA-based Biota Pharmaceuticals saw its shares slump 29% to a record low of $2.29 on Friday, after the…

Anti-viralsAntibiotics and Infectious diseasesBiota PharmaceuticalsFinancialPharmaceuticalResearchUSA

Expensive new hepatitis C drugs are worth the investment

Expensive new hepatitis C drugs are worth the investment

21-07-2014

The debate over the high price of new Hepatitis C Virus (HCV) drugs has focused on the price per pill,…

Anti-viralsCVS CaremarkGilead SciencesHepatitis CPharmaceuticalPricingSovaldiUSA

Report: US state governments may spend $55 billion on hepatitis C drugs

Report: US state governments may spend $55 billion on hepatitis C drugs

17-07-2014

State legislatures in the USA will need to find billions in their budgets to purchase costly new hepatitis…

Anti-viralsExpress ScriptsFinancialGilead SciencesHealthcarePharmaceuticalSovaldiUSA

Drug-treated hepatitis C population to more than double by 2016

Drug-treated hepatitis C population to more than double by 2016

16-07-2014

The hepatitis C virus population is already large, with 2 million diagnosed, chronically infected cases…

Anti-viralsCytokinesDaklinzaDecision Resources GroupEuropeHepatitis CInterferonJapanMarkets & MarketingPharmaceuticalUSA

EMA validates Marketing Authorization Applications for AbbVie’s hepatitis C treatment

EMA validates Marketing Authorization Applications for AbbVie’s hepatitis C treatment

17-06-2014

US drugmaker AbbVie announced today that the Marketing Authorization Applications (MAAs) for its investigational,…

AbbVieAnti-viralsPharmaceuticalRegulationRitonavir TabletsUSA

AbbVie files for EU marketing approval for its all-oral, interferon-free hepatitis C therapy

AbbVie files for EU marketing approval for its all-oral, interferon-free hepatitis C therapy

08-05-2014

US drugmaker AbbVie has submitted marketing authorization applications to the European Medicines Agency…

AbbVieAnti-viralsPharmaceuticalRegulationUSA

AbbVie files NDA for oral, interferon-free treatment of hepatitis C

22-04-2014

US drugmaker AbbVie has submitted its New Drug Application to the US Food and Drug Administration for…

AbbVieAnti-viralsEnanta PharmaceuticalsFinancialNorth AmericaPharmaceuticalRegulationUSA

1 to 25 of 33 results

Back to top